SAN FRANCISCO--(BUSINESS WIRE)--ACT Biotech Inc., a privately held biotechnology company developing a portfolio of best-in-class oral kinase inhibitors as anti-cancer drugs, today announced the treatment of the first patients in a Phase 2 clinical trial of Telatinib in combination with standard-of-care chemotherapy for the treatment of gastric cancer. The Phase 2 multi-center trial is being conducted in the U.S. and in Spain with Principal Investigators at the University of Texas MD Anderson Cancer Center in Houston, Texas and the Vall d’Hebron University Hospital in Barcelona, Spain.
